I thought the earnings were pretty decent. Obviously the market disagrees but I would love to hear your opinions of the earnings and today’s consequent drop in price.
02:35 AM EST, 02/10/2026 (MT Newswires) -- GSK (GSK.L) said China's Center for Drug Evaluation accepted for review its application for Arexvy as a vaccine in adults against respiratory syncytial virus-caused lower respiratory tract disease. According to a Tuesday filing, the British drugmaker is seeking approval in China for the use of the vaccine in adults aged at least 60 years. It supported the application with positive data from a phase 3 trial, and a regulatory decision is expected in 2027.
I thought the results today were decent, nice dividend growth for the upcoming and next year as well as the share buybacks. Market seems happy with the results what do you all think?
News on a new purchase for $GSK to strengthen its position in respiratory, immunology & inflammation offerings.
https://www.reuters.com/business/healthcare-pharmaceuticals/gsk-buy-rapt-therapeutics-22-billion-2026-01-20/
GSK Q3 2025 Earnings in 5 Days: Execution vs. FX & IRA headwinds
When: Wed 29 Oct 2025, 07:00 GMT; management presentation follows (webcast link on GSK IR).
Street sees steady quarter with specialty meds leading; focus on whether FY25 stays “top-end” of guidance as FX and US policy headwinds bite.
4 Key Takeaways
• Consensus (Q3’25E): Turnover £8.24bn, Core EPS ~47.1p, Op. margin ~32.4%; WANS ~4,036m (buybacks reduce share count).
• FY25 Guidance (CER): Sales +3–5%, Core OP +6–8%, Core EPS +6–8%, management guiding toward the top end.
• Returns: FY25 dividend run-rate ~64p indicated earlier; £2bn buyback programme underway (three tranches completed/underway YTD).
• Watchpoints (Q3): FX −1% to −2% drag on sales; US IRA Part D redesign ~£400–500m FY headwind; step-up in SG&A to support launches; vaccine mix (Shingrix/Arexvy seasonality) and oncology momentum (Jemperli/Ojjaara).
⭐ Star Rating
• Dividend Strength: ⭐⭐⭐⭐☆
• Financial Health: ⭐⭐⭐⭐☆
• Growth/Pipeline: ⭐⭐⭐☆☆
• Valuation: ⭐⭐⭐☆☆
• Management/Execution: ⭐⭐⭐⭐☆
Overall: ⭐⭐⭐⭐☆ (4/5) Solid execution and shareholder returns; mind FX/IRA and vaccine mix into Q4.
If specialty meds + oncology keep comping strong and FX/IRA headwinds are contained, GSK can hold the top-end FY25 guide. I’ll be watching EPS leverage vs. SG&A step-up and any colour on Arexvy/Shingrix trajectory into Q4.
ccc1990
8 mesi fa
Lovely stuff
ContrarianCNT
8 mesi fa
What's happening guys?
Unable to check what's going on. Biggest daily pop I can remember on GSK.
Questa pagina potrebbe includere contenuti generati dalla comunità, di cui Trading 212 non è responsabile. Svolgi sempre le tue ricerche. Trading 212 fornisce un servizio di sola esecuzione e non offre consigli di investimento o gestione del portafoglio.
Compra e vendi GSK PLC +48,8 GBX (2,64%) e oltre 13.000 azioni ed ETF globali
Scarica l'app
Apri account
Potrebbero essere applicate ulteriori commissioni. Visualizza i nostri termini e commissioni.
Compra azioni immediatamente
Scegli l'azienda che preferisci
Seleziona quanto investire
Ottieni le tue azioni in un attimo
Creare ricchezza è un'abitudine. Automatizzala con un pie.
Investi in pies preimpostati o crea il tuo scegliendo tra migliaia di azioni ed ETF.
Scopri di più
Scopri di più
Guarda il video
Arriva a possedere perfino le azioni più costose come quelle di Google, Amazon e Apple
Guarda il video
Euronext Paris
NYSE, NASDAQ
Xetra, Gettex
Euronext Amsterdam
Bolsa de Madrid
Wiener Börse
Borsa di Londra
Euronext Lisbon
Euronext Paris
NYSE, NASDAQ
Xetra, Gettex
Euronext Amsterdam
Bolsa de Madrid
Wiener Börse
Borsa di Londra
Euronext Lisbon
Vedi tutti gli strumenti di trading
Assistenza 24/7
Tempo di risposta medio di 29 secondi
Inizia subito a creare un patrimonio
Unisciti a oltre 5 milioni di utenti
Scarica l'app
Apri account
Scarica l'app per dispositivi mobili
Tutte le statistiche presentate sono globali. Il numero di clienti rappresenta gli Accounts finanziati.
Eccellente
Valutato 4,6 / 5 in base a 93.567 recensioni su
Trustpilot
Valutato 4,6 / 5 in base a 93.567 recensioni su
Trustpilot
Invitato
Great
Immediate updates, easy to use and manage.
Invitato
Very easy to use
Very easy to use. Intuitive app and makes it straight forward to sit back and let your investment's do its work
Invitato
Ease of use
Easy to set up an account
Easy to transfer funds
Great interest rate
Great all round experience
Invitato
Easy to set up my account
Easy to set up my account easy to access balance and a very good rate in interest.
Invitato
easy to use platform
easy to use platform, love the ability to transfer cash isa funds into stocks and shares isa
Invitato
Simple and Informative platform
I wanted a platform which was offering great rates for my ISA, but discovered not only did this platform do that. It also gave me an insight into trading and world markets. It's quite simply brilliant.
Invitato
Great app that provides all my account…
Great app that provides all my account info at my fingertips
Invitato
Easy to use.
Easy to use.
Can view everything simply.
Just what I need.
Invitato
Good interest rate and can take the…
Good interest rate and can take the money out whenever I want.
Invitato
So easy
So easy! Makes investing a pleasure
Invitato
I’m novice and useless with technology…
I’m novice and useless with technology but I found this an easy site to navigate and to deal with.
Invitato
Nice app
Great app, very intuitive and simple to use. Gold standard.
Invitato
Very easy to use
Very easy to use. Very clear. And a joy to watch my savings rise
Invitato
Easy to use
Functional and easy to use and track my cash & stocks & shares isas
Invitato
Easy access to my account and how Easy…
Easy access to my account and how Easy it is to navigate the212 application.
Invitato
Simple and easy to use app
Simple and easy to use app. Ease of setting up recurring payments. Great for a beginner that has no prior knowledge or experience of investing.
Invitato
Easy and simple app
Easy and simple app, tells you daily your interest which I like and I get emails. The updating is really good.
Invitato
Very easy and highly recommend
Very easy and highly recommend. Straight forward to use and cost instructions on the fees and charges.
Invitato
Great way for your money to build
Just very pleased with the level of savings rate and steady build up.
Invitato
Cool app
User friendly mobile app that makes investing easy and funny. Fast navigation throughout the app. In a few clicks can see basically every information one might require.
Ecco alcune delle recensioni positive da parte dei clienti.
I nostri premi
Domande frequenti
Qual è il prezzo dell’azione GSK (GSK)?
Il prezzo attuale di GSK (GSK) è 1900,3 GBX.
Qual è il massimo a 52 settimane di GSK?
Il massimo a 52 settimane per GSK è 2281,7 GBX.
Qual è il minimo a 52 settimane di GSK?
Il minimo a 52 settimane per GSK è 1318,7 GBX.
Qual è l’andamento settimanale di GSK?
Nell’ultima settimana, il prezzo di GSK è cambiato di -0,92%.
Qual è la performance mensile di GSK?
Nell’ultimo mese, il prezzo di GSK è cambiato di -0,04%.
Qual è la performance a 3 mesi di GSK?
Negli ultimi tre mesi, il prezzo di GSK è cambiato di -10,45%.
Qual è la performance a 6 mesi di GSK?
Negli ultimi sei mesi, il prezzo di GSK è cambiato di 3,67%.
Qual è il rendimento annuale di GSK?
Nel corso dell’ultimo anno, il prezzo di GSK è cambiato di 27,97%.